Braveheart Bio (NASDAQ:BRVE) Reaches New 12-Month Low – Should You Sell?

Braveheart Bio, Inc. (NASDAQ:BRVE) shares reached a new 52-week low on Thursday. The company traded as low as $17.42 and last traded at $17.5240, with a volume of 33,143 shares changing hands. The stock had previously closed at $20.10.

Wall Street Analysts Forecast Growth

BRVE has been the topic of several recent research reports. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective on the stock. Zacks Research upgraded shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. TD Cowen assumed coverage on Braveheart Bio in a report on Monday, August 31st. They issued a “buy” rating for the company. Weiss Ratings initiated coverage on shares of Braveheart Bio in a research report on Monday. They issued a “sell (d-)” rating on the stock. Finally, Wall Street Zen raised Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Braveheart Bio Price Performance

The company has a market cap of $1.58 billion and a P/E ratio of -6.96. The stock’s 50-day simple moving average is $23.11.

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($2.26). Research analysts forecast that Braveheart Bio, Inc. will post -1.99 EPS for the current fiscal year.

Insider Activity

In other Braveheart Bio news, Director Orbimed Advisors Llc bought 1,940,000 shares of Braveheart Bio stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the transaction, the director directly owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This represents a 19.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the acquisition, the insider owned 10,232,420 shares of the company’s stock, valued at approximately $184,183,560. This represents a 12.05% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.